 Nes Ziona, Israel, Aug. 15, 2021 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. Nasdaq: ENLV, the Company, a clinical-stage macrophage reprogramming immunotherapy company, today reported that after reviewing previously-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a proposed Company-sponsored, multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome ARDS. 